Maeshima Akiko Miyagi, Taniguchi Hirokazu, Toyoda Kosuke, Yamauchi Nobuhiko, Makita Shinichi, Fukuhara Suguru, Munakata Wataru, Maruyama Dai, Kobayashi Yukio, Tobinai Kensei
Department of Pathology, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Hematology, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Br J Haematol. 2016 Sep;174(6):923-31. doi: 10.1111/bjh.14153. Epub 2016 Jul 27.
This study analysed incidence, patient outcome, immunophenotype and prognostic factors of histological transformation (HT) from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) to diffuse large B-cell lymphoma (DLBCL) in 467 patients (median age, 61 years). The primary sites of MALT lymphoma were the stomach (43%), ocular adnexa (25%), lung (8%), systemic (8%) and other tissues (16%). HT occurred in 8% of MALT lymphomas. Risk of HT by 15 years was 5%: 4% in limited-stage diseases (n = 385) and 16% in advanced-stage diseases (n = 56) (P = 0·02). The median time to HT was 48 months (range, 4-139). Five-year progression-free survival (PFS) and overall survival (OS) rates after HT were 80% and 94%, respectively. Immunohistochemical results of DLBCL were as follows: germinal centre B-cell (GCB)/non-GCB, 37%/63%; CD10, 9%; BCL6, 59%; MUM1, 38%; MYC, 42%; BCL2, 35%; Ki67 ≥ 90%, 23%; and CD5, 3%. The majority (75%, 9/12) of GCB-type DLBCLs exhibited CD10(-) , BCL6(+) and MUM1(-) immunophenotypes; the remainder had CD10(+) immunophenotypes. Multivariate analysis revealed that only advanced stage at HT was a significant adverse factor for PFS (P = 0·037). Thus, overall risk of HT was low and prognosis after HT was favourable; however, in advanced-stage cases, risk of HT was relatively high and prognosis was unfavourable.
本研究分析了467例(中位年龄61岁)黏膜相关淋巴组织结外边缘区B细胞淋巴瘤(MALT淋巴瘤)转化为弥漫性大B细胞淋巴瘤(DLBCL)的组织学转化(HT)的发生率、患者结局、免疫表型及预后因素。MALT淋巴瘤的原发部位为胃(43%)、眼附属器(25%)、肺(8%)、全身(8%)和其他组织(16%)。8%的MALT淋巴瘤发生了HT。15年时HT的风险为5%:局限期疾病(n = 385)为4%,晚期疾病(n = 56)为16%(P = 0.02)。HT的中位时间为48个月(范围4 - 139个月)。HT后5年无进展生存(PFS)率和总生存(OS)率分别为80%和94%。DLBCL的免疫组化结果如下:生发中心B细胞(GCB)/非GCB,37%/63%;CD10,9%;BCL6,59%;MUM1,38%;MYC,42%;BCL2,35%;Ki67≥90%,23%;CD5,3%。大多数(75%,9/12)GCB型DLBCL表现为CD10(-)、BCL6(+)和MUM1(-)免疫表型;其余具有CD10(+)免疫表型。多变量分析显示,仅HT时的晚期是PFS的显著不良因素(P = 0.037)。因此,HT的总体风险较低,HT后的预后良好;然而,在晚期病例中,HT的风险相对较高且预后不良。